1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. Apontis Pharma AG
  6. News
  7. Summary
    APPH   DE000A3CMGM5

APONTIS PHARMA AG

(APPH)
  Report
Real-time Estimate Tradegate  -  05/25 07:19:35 am EDT
13.33 EUR   -2.74%
01:32aAPONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million
EQ
05/12APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities
EQ
05/12Apontis Pharma AG Announces Redesignations in New Supervisory Board
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

APONTIS PHARMA and Midas Pharma announce development partnership to launch Single Pill with pan-European intellectual property rights

12/14/2021 | 01:32am EDT

DGAP-News: APONTIS PHARMA AG / Key word(s): Product Launch/Alliance
APONTIS PHARMA and Midas Pharma announce development partnership to launch Single Pill with pan-European intellectual property rights

14.12.2021 / 07:30
The issuer is solely responsible for the content of this announcement.


APONTIS PHARMA and Midas Pharma announce development partnership to launch Single Pill with pan-European intellectual property rights
 

  • Continued expansion of the mid-term Single Pill portfolio for the treatment of hypertension
  • APONTIS PHARMA for the first time owns all Europe-wide rights (IP - Intellectual Property) to the preparation, medication, or Single Pill
 

Monheim am Rhein, 14 December 2021. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, continues to consistently implement its communicated growth strategy. Today the Single Pill Company announces a development partnership with the German company Midas Pharma. The objective is the contract development of a Single Pill with a combination of three leading active ingredients for the treatment of high blood pressure (hypertension). The development of this Single Pill will further strengthen APONTIS PHARMA's portfolio in the medium term.

For the first time, APONTIS PHARMA owns the EU-wide rights (IP - Intellectual Property) to the combined medication. As a result, the Company has new opportunities in terms of out-licensing for marketing and distribution beyond the borders of its home market in Germany. The Single Pill addresses a large and continuously growing group of hypertension patients. In Germany alone, around 225,000 people are currently taking a loose combination of the three active ingredient classes. By the time the product is launched on the market in 2026, the two partner companies expect around 360,000 people to use it. This corresponds to an average annual growth rate of more than ten percent.

The Single Pill therapy approach is well proven. Combining up to three active ingredients in just one tablet increases patient compliance compared to loose combinations. It is the basis for a more efficient and thus more successful therapy. Compared to conventional therapies, Single Pills sustainably reduce event rates and hospitalizations. The success of the Single Pill therapy strategy is proven by the START study conducted in 2019. As a result, patients benefit from a Single Pill versus a substance-matched Multi Pill regimen.

"The established, trusting partnership with Midas Pharma for Single Pill developments has so far exclusively covered the German market. For this reason, this new development partnership represents a milestone in APONTIS PHARMA's corporate history. For the first time, we have EU-wide property rights for the medication and can thus reach patients in additional country markets. We are pleased to have a competent and experienced partner in Midas Pharma at our side who shares our vision of a more efficient, innovation-driven therapy," says Karlheinz Gast, Chief Executive Officer (CEO) of APONTIS PHARMA AG.

"Our two companies have already been working together in a spirit of trust for many years on a whole range of new combination products. APONTIS PHARMA and Midas Pharma have an innovative and effective approach to Single Pills. As a strategic partner for global pharmaceutical projects, especially as a developer and supplier (CDMO) of products and provider of complementary services along the pharmaceutical value chain, we have developed a great deal of expertise. The two partners jointly contribute their strengths to support a dynamically growing patient group in their therapy with Single Pill products," says Karl-Heinz Schleicher, owner, and CEO of Midas Pharma.

About Midas Pharma:

Midas Pharma is a pharmaceutical company based in Ingelheim, Germany, that offers products, services and expertise along the entire pharmaceutical value chain - from Starting Materials and Active Pharmaceutical Ingredients to market ready Finished Products and Devices.

Since over three decades the family-owned company has successfully contributed to the Pharma sector and has step by step expanded its competencies. For 2021 Midas Pharma Group is expecting an annual turnover of about 400 Mio. EUR.

With more than 250 employees and 10 locations in all major pharmaceutical markets worldwide Midas Pharma has excellent local know-how, local contacts and well-established networks in different pharmaceutical sectors (biological products, small molecules and medical devices).

Thanks to many years of experience and extensive expertise, Midas Pharma has a proven track record of successfully supporting its customers in coordinating even complex pharmaceutical projects and creating significant added value.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three patent-free active ingredients in a single dosage form. APONTIS PHARMA develops, promotes, and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia, and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical regions. From here, the Company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Press Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
Sara Pinto
ir@apontis-pharma.de
T: +49 89 125 09 0330



14.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: APONTIS PHARMA AG
Alfred-Nobel-Str. 10
40789 Monheim
Germany
E-mail: info@apontis-pharma.de
Internet: https://apontis-pharma.de/
ISIN: DE000A3CMGM5
WKN: A3CMGM
Listed: Regulated Unofficial Market in Frankfurt (Scale)
EQS News ID: 1257310

 
End of News DGAP News Service

1257310  14.12.2021 

fncls.ssp?fn=show_t_gif&application_id=1257310&application_name=news&site_id=zonebourse_sftp

© EQS 2021
All news about APONTIS PHARMA AG
01:32aAPONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2..
EQ
05/12APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda item..
EQ
05/12Apontis Pharma AG Announces Redesignations in New Supervisory Board
CI
05/10APONTIS PHARMA continues strong profitable growth in Q1 2022
EQ
05/10Apontis Pharma AG Provides Revenue Guidance for the Year 2022
CI
05/05APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Singl..
EQ
05/05Apontis Pharma and Develco Pharma Enter Development Partnership for Launch of Two Singl..
CI
04/20APONTIS PHARMA : START study published in scientific journal - Cost reduction in the treat..
EQ
04/20Apontis Pharma Ag Announces Publication of Data on the Pharmacoeconomics of the Unique ..
CI
03/16APONTIS PHARMA : START study published in scientific journal - Lower incidence of cardiova..
EQ
More news
Financials
Sales 2022 55,9 M 59,9 M 59,9 M
Net income 2022 2,53 M 2,72 M 2,72 M
Net cash 2022 26,8 M 28,8 M 28,8 M
P/E ratio 2022 46,7x
Yield 2022 -
Capitalization 116 M 125 M 125 M
EV / Sales 2022 1,60x
EV / Sales 2023 1,63x
Nbr of Employees 148
Free-Float 100%
Chart APONTIS PHARMA AG
Duration : Period :
Apontis Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 13,70 €
Average target price 29,00 €
Spread / Average Target 112%
EPS Revisions
Managers and Directors
Karlheinz Gast Chief Executive Officer
Thomas Zimmermann Chief Financial Officer
Edin Hadzic Chairman-Supervisory Board
Olaf Randerath Head-Medical Affairs
Olaf Elbracht Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
APONTIS PHARMA AG-27.13%125
JOHNSON & JOHNSON6.04%477 336
PFIZER, INC.-9.55%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494